Organization (Industry)
Seqirus (United Kingdom)
ClinicalTrials.gov lists Seqirus (United Kingdom) as lead sponsor of 53 trials. It has 46 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Seqirus (United Kingdom): 53 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (5)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Influenza, Human | 56 |
| Influenza in Birds | 4 |
| Rhinitis, Allergic | 2 |
| COVID-19 | 1 |
| Community-Acquired Pneumonia | 1 |
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 4 |
| 2016 | 6 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: none of the 53 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (46)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Comparator QIV | Influenza, Human | Phase 3 | 3 |
| QIVc | Influenza, Human | Phase 3 | 3 |
| Comparator | Influenza, Human | Phase 3 | 2 |
| Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV) | Influenza, Human | Phase 3 | 2 |
| licensed QIVr | Influenza, Human | Phase 3 | 1 |
Showing 5 of 46 active programs.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Trivalent Influenza Vaccine | 4 |
| CSL Limited Influenza Virus Vaccine | 2 |
| CSL Influenza Vaccine | 2 |
| Inactivated Influenza Vaccine | 1 |
| bioCSL Trivalent Influenza Virus Vaccine (CSL TIV) | 1 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 64% hit target (n=14) | 47% on time (n=17) |
Journals published in (25)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Vaccine | 16 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 4 |
| Human vaccines & immunotherapeutics | 3 |
| JAMA | 3 |
| Pediatrics | 2 |
Showing 5 of 25 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 2 | 2025-01-21 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 5 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Seqirus Inc | Holly Springs, US | EMA, FDA, Health Canada |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Novartis Vaccines | Co sponsors trial with | 2 |
Latest dated events (69)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-05 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-01-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-03-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-01-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 69 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| SEQIRUS, INC | Certificate of waiver | Terminated |
Biomarker capability evidence (9)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FAS | Trial sponsor | Primary endpoint in a Phase 3 trial |
| FASN | Trial sponsor | Primary endpoint in a Phase 3 trial |
| CSHL1 | Trial sponsor | Mentioned in trial text |
| CSHL1 | Trial sponsor | Mentioned in trial text |
| CSHL1 | Trial sponsor | Mentioned in trial text |
Showing 5 of 9 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, and biomarkers this organization publishes on.